Today's FierceBiotech Research

Arsalan Arif, Fierce Life Sciences publisher

Earlier today, we inadvertently sent you the current issue of FierceBiotech Research, the weekly R&D sister publication to FierceBiotech. We apologize for the error, and you will not be sent FierceBiotech Research in the future. 

If you'd prefer to opt-in and begin a free subscription to FierceBiotech Research, please click here. 

Arsalan Arif
Publisher, Fierce Life Sciences
Email | Follow me on Twitter

Suggested Articles

The duo will carry out a phase 2 study of BioNTech’s mRNA cancer immunotherapy in combination with Sanofi and Regeneron’s PD-1 blocker, Libtayo.

Merck was purposely cautious during the start of the pandemic when it came to vaccine development but is now slowly but surely ramping up its efforts

The money will equip AlloVir to embark on a broad clinical development program for a phase 3-ready cell therapy that targets five viruses.